Skip to content

Study on the application of breast cancer bone metastasis organoid model in individualized drug screening

Study on the application of breast cancer bone metastasis organoid model in individualized drug screening

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037237
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast canter

Interventions

Group of breast cancer bone matastasis:Nil

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Have been diagnosed as breast cancer bone matastasis; 2. No serious underlying diseases; 3. Agree to continue to receive treatment and follow-up in our hospital after diagnosis 4. Pathologically diagnosed as breast cancer; 5. No significant disfunction of heart, lung, or kidney and no HIV or syphilis infection; 6. All patients should sign an informed consent form when selected.

Exclusion criteria

Exclusion criteria: 1. The general condition of patients is poor, and it is estimated that they cannot tolerate chemotherapy and targeted therapy; 2. Patients with brain metastases; 3. Patients with unstable angina, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months, prolonged QT interval (>450ms); 4. Malignant tumors in other parts appeared within the last 5 years; 5. The patient cannot be followed up or is participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
progression-free survival;

Countries

China

Contacts

Public ContactWending Huang

Fudan University Shanghai Cancer Center

orienthwd@163.com+86 18616182390

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026